Photographer Henry Diltz climbed a mountain with The Eagles, rode horseback with America, and 'rolled a fatty' with Neil ...

Scholar Rock Holding Corporation (NASDAQ:SRRK) is among the 11 Best GLP-1 and Weight Loss Stocks to Invest in.

Operator: Good morning, ladies and gentlemen, and welcome to the Scholar Rock Second Quarter 2025 Business Update Conference Call. [Operator Instructions] This call is being recorded […] ...

Scholar Rock Holding SRRK -4.80% + Free Alerts has outperformed the market over the past 5 years by 7.22% on an annualized basis producing an average annual return of 21.06%. Currently, Scholar Rock ...

It didn't take a high-powered academic to figure out why Scholar Rock 's (NASDAQ: SRRK) share price swooned by more than 5% ...

No revenue was recorded as the company remains pre-commercial, in line with analyst expectations. R&D and G&A expenses surged 47% and 191% year over year as apitegromab advanced toward anticipated U.S ...

Scholar Rock to Host Conference Call to Discuss Second Quarter 2025 Financial Results and Provide Business Update on August 6, 2025 Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical ...

Scholar Rock to Present Comprehensive Update at 2025 Annual Cure SMA Research and Clinical Care Meeting, Including Positive Results from Pivotal Phase 3 SAPPHIRE Trial ...

Although there are many examples throughout history of positive changes in top company management teams, important personnel moves tend to unsettle investors. Scholar Rock's C-suite now looks ...

Biotech stock Scholar Rock (SRRK -1.28%) was popular among investors on Wednesday after a positive new analyst note on the company made the rounds.

Scholar Rock, a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy, cardiometabolic disorders, and other serious diseases where protein ...

I analyze Scholar Rock's promising Phase 3 results for SMA drug, but warn of financial challenges and recommend a Hold rating. Read more here.